nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Azathioprine—systemic scleroderma	0.778	1	CbGbCtD
Deferoxamine—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000425	0.00191	CcSEcCtD
Deferoxamine—Abdominal pain—Mometasone—systemic scleroderma	0.000423	0.00191	CcSEcCtD
Deferoxamine—Body temperature increased—Mometasone—systemic scleroderma	0.000423	0.00191	CcSEcCtD
Deferoxamine—Mediastinal disorder—Lisinopril—systemic scleroderma	0.000423	0.0019	CcSEcCtD
Deferoxamine—Paraesthesia—Captopril—systemic scleroderma	0.000422	0.0019	CcSEcCtD
Deferoxamine—Dyspnoea—Captopril—systemic scleroderma	0.000419	0.00189	CcSEcCtD
Deferoxamine—Arrhythmia—Lisinopril—systemic scleroderma	0.000419	0.00188	CcSEcCtD
Deferoxamine—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.000418	0.00188	CcSEcCtD
Deferoxamine—Dizziness—Pentoxifylline—systemic scleroderma	0.00041	0.00185	CcSEcCtD
Deferoxamine—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.000409	0.00184	CcSEcCtD
Deferoxamine—Erythema—Lisinopril—systemic scleroderma	0.000408	0.00184	CcSEcCtD
Deferoxamine—Infection—Azathioprine—systemic scleroderma	0.000408	0.00184	CcSEcCtD
Deferoxamine—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000406	0.00183	CcSEcCtD
Deferoxamine—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000406	0.00183	CcSEcCtD
Deferoxamine—Arthralgia—Leflunomide—systemic scleroderma	0.000404	0.00182	CcSEcCtD
Deferoxamine—Myalgia—Leflunomide—systemic scleroderma	0.000404	0.00182	CcSEcCtD
Deferoxamine—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000404	0.00182	CcSEcCtD
Deferoxamine—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000403	0.00181	CcSEcCtD
Deferoxamine—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000402	0.00181	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000402	0.00181	CcSEcCtD
Deferoxamine—Skin disorder—Azathioprine—systemic scleroderma	0.000399	0.00179	CcSEcCtD
Deferoxamine—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.000396	0.00178	CcSEcCtD
Deferoxamine—Vomiting—Pentoxifylline—systemic scleroderma	0.000395	0.00178	CcSEcCtD
Deferoxamine—Convulsion—Mycophenolic acid—systemic scleroderma	0.000393	0.00177	CcSEcCtD
Deferoxamine—Muscle spasms—Lisinopril—systemic scleroderma	0.000392	0.00177	CcSEcCtD
Deferoxamine—Headache—Pentoxifylline—systemic scleroderma	0.000389	0.00175	CcSEcCtD
Deferoxamine—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000388	0.00174	CcSEcCtD
Deferoxamine—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000386	0.00174	CcSEcCtD
Deferoxamine—Myalgia—Mycophenolic acid—systemic scleroderma	0.000386	0.00174	CcSEcCtD
Deferoxamine—Infection—Leflunomide—systemic scleroderma	0.000385	0.00173	CcSEcCtD
Deferoxamine—Vision blurred—Lisinopril—systemic scleroderma	0.000385	0.00173	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Captopril—systemic scleroderma	0.000385	0.00173	CcSEcCtD
Deferoxamine—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000384	0.00173	CcSEcCtD
Deferoxamine—Hypotension—Azathioprine—systemic scleroderma	0.000384	0.00173	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000383	0.00172	CcSEcCtD
Deferoxamine—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.000383	0.00172	CcSEcCtD
Deferoxamine—Nervous system disorder—Leflunomide—systemic scleroderma	0.00038	0.00171	CcSEcCtD
Deferoxamine—Thrombocytopenia—Leflunomide—systemic scleroderma	0.00038	0.00171	CcSEcCtD
Deferoxamine—Pruritus—Mometasone—systemic scleroderma	0.000379	0.00171	CcSEcCtD
Deferoxamine—Tachycardia—Leflunomide—systemic scleroderma	0.000378	0.0017	CcSEcCtD
Deferoxamine—Skin disorder—Leflunomide—systemic scleroderma	0.000377	0.00169	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000374	0.00168	CcSEcCtD
Deferoxamine—Angioedema—Lisinopril—systemic scleroderma	0.000373	0.00168	CcSEcCtD
Deferoxamine—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000373	0.00168	CcSEcCtD
Deferoxamine—Abdominal pain—Captopril—systemic scleroderma	0.000372	0.00167	CcSEcCtD
Deferoxamine—Body temperature increased—Captopril—systemic scleroderma	0.000372	0.00167	CcSEcCtD
Deferoxamine—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00037	0.00167	CcSEcCtD
Deferoxamine—Oedema—Mycophenolic acid—systemic scleroderma	0.00037	0.00166	CcSEcCtD
Deferoxamine—Nausea—Pentoxifylline—systemic scleroderma	0.000369	0.00166	CcSEcCtD
Deferoxamine—Infection—Mycophenolic acid—systemic scleroderma	0.000367	0.00165	CcSEcCtD
Deferoxamine—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.000367	0.00165	CcSEcCtD
Deferoxamine—Diarrhoea—Mometasone—systemic scleroderma	0.000366	0.00165	CcSEcCtD
Deferoxamine—Leukopenia—Lisinopril—systemic scleroderma	0.000365	0.00164	CcSEcCtD
Deferoxamine—Renal failure acute—Methotrexate—systemic scleroderma	0.000364	0.00164	CcSEcCtD
Deferoxamine—Shock—Mycophenolic acid—systemic scleroderma	0.000364	0.00164	CcSEcCtD
Deferoxamine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000363	0.00163	CcSEcCtD
Deferoxamine—Hypotension—Leflunomide—systemic scleroderma	0.000362	0.00163	CcSEcCtD
Deferoxamine—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000362	0.00163	CcSEcCtD
Deferoxamine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000361	0.00162	CcSEcCtD
Deferoxamine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000359	0.00162	CcSEcCtD
Deferoxamine—Visual disturbance—Methotrexate—systemic scleroderma	0.000355	0.0016	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000354	0.00159	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000353	0.00159	CcSEcCtD
Deferoxamine—Paraesthesia—Leflunomide—systemic scleroderma	0.000348	0.00157	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.000348	0.00156	CcSEcCtD
Deferoxamine—Arthralgia—Lisinopril—systemic scleroderma	0.000347	0.00156	CcSEcCtD
Deferoxamine—Myalgia—Lisinopril—systemic scleroderma	0.000347	0.00156	CcSEcCtD
Deferoxamine—Dyspnoea—Leflunomide—systemic scleroderma	0.000346	0.00156	CcSEcCtD
Deferoxamine—Hypotension—Mycophenolic acid—systemic scleroderma	0.000346	0.00156	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000345	0.00155	CcSEcCtD
Deferoxamine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000344	0.00155	CcSEcCtD
Deferoxamine—Vomiting—Mometasone—systemic scleroderma	0.00034	0.00153	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000337	0.00152	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000336	0.00151	CcSEcCtD
Deferoxamine—Headache—Mometasone—systemic scleroderma	0.000335	0.00151	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000335	0.00151	CcSEcCtD
Deferoxamine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000333	0.0015	CcSEcCtD
Deferoxamine—Oedema—Lisinopril—systemic scleroderma	0.000333	0.0015	CcSEcCtD
Deferoxamine—Pruritus—Captopril—systemic scleroderma	0.000333	0.0015	CcSEcCtD
Deferoxamine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000332	0.00149	CcSEcCtD
Deferoxamine—Pain—Leflunomide—systemic scleroderma	0.000331	0.00149	CcSEcCtD
Deferoxamine—Infection—Lisinopril—systemic scleroderma	0.000331	0.00149	CcSEcCtD
Deferoxamine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00033	0.00148	CcSEcCtD
Deferoxamine—Shock—Lisinopril—systemic scleroderma	0.000328	0.00147	CcSEcCtD
Deferoxamine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000327	0.00147	CcSEcCtD
Deferoxamine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000326	0.00147	CcSEcCtD
Deferoxamine—Tachycardia—Lisinopril—systemic scleroderma	0.000325	0.00146	CcSEcCtD
Deferoxamine—Body temperature increased—Azathioprine—systemic scleroderma	0.000324	0.00146	CcSEcCtD
Deferoxamine—Abdominal pain—Azathioprine—systemic scleroderma	0.000324	0.00146	CcSEcCtD
Deferoxamine—Skin disorder—Lisinopril—systemic scleroderma	0.000324	0.00146	CcSEcCtD
Deferoxamine—Diarrhoea—Captopril—systemic scleroderma	0.000322	0.00145	CcSEcCtD
Deferoxamine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00032	0.00144	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000319	0.00144	CcSEcCtD
Deferoxamine—Nausea—Mometasone—systemic scleroderma	0.000318	0.00143	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000317	0.00143	CcSEcCtD
Deferoxamine—Pain—Mycophenolic acid—systemic scleroderma	0.000316	0.00142	CcSEcCtD
Deferoxamine—Hypotension—Lisinopril—systemic scleroderma	0.000311	0.0014	CcSEcCtD
Deferoxamine—Dizziness—Captopril—systemic scleroderma	0.000311	0.0014	CcSEcCtD
Deferoxamine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00031	0.00139	CcSEcCtD
Deferoxamine—Urticaria—Leflunomide—systemic scleroderma	0.000308	0.00139	CcSEcCtD
Deferoxamine—Abdominal pain—Leflunomide—systemic scleroderma	0.000306	0.00138	CcSEcCtD
Deferoxamine—Body temperature increased—Leflunomide—systemic scleroderma	0.000306	0.00138	CcSEcCtD
Deferoxamine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000304	0.00137	CcSEcCtD
Deferoxamine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000304	0.00137	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000304	0.00137	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000303	0.00137	CcSEcCtD
Deferoxamine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000302	0.00136	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000302	0.00136	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000302	0.00136	CcSEcCtD
Deferoxamine—Paraesthesia—Lisinopril—systemic scleroderma	0.000299	0.00135	CcSEcCtD
Deferoxamine—Vomiting—Captopril—systemic scleroderma	0.000299	0.00135	CcSEcCtD
Deferoxamine—Dyspnoea—Lisinopril—systemic scleroderma	0.000297	0.00134	CcSEcCtD
Deferoxamine—Headache—Captopril—systemic scleroderma	0.000295	0.00133	CcSEcCtD
Deferoxamine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000292	0.00132	CcSEcCtD
Deferoxamine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000292	0.00132	CcSEcCtD
Deferoxamine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000292	0.00131	CcSEcCtD
Deferoxamine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000292	0.00131	CcSEcCtD
Deferoxamine—Asthma—Methotrexate—systemic scleroderma	0.000291	0.00131	CcSEcCtD
Deferoxamine—Infection—Mycophenolate mofetil—systemic scleroderma	0.00029	0.0013	CcSEcCtD
Deferoxamine—Eosinophilia—Methotrexate—systemic scleroderma	0.000288	0.0013	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000288	0.00129	CcSEcCtD
Deferoxamine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000287	0.00129	CcSEcCtD
Deferoxamine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000286	0.00129	CcSEcCtD
Deferoxamine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000286	0.00129	CcSEcCtD
Deferoxamine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000286	0.00129	CcSEcCtD
Deferoxamine—Pain—Lisinopril—systemic scleroderma	0.000285	0.00128	CcSEcCtD
Deferoxamine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000285	0.00128	CcSEcCtD
Deferoxamine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000283	0.00128	CcSEcCtD
Deferoxamine—Bradycardia—Prednisone—systemic scleroderma	0.000283	0.00128	CcSEcCtD
Deferoxamine—Diarrhoea—Azathioprine—systemic scleroderma	0.000281	0.00126	CcSEcCtD
Deferoxamine—Nausea—Captopril—systemic scleroderma	0.000279	0.00126	CcSEcCtD
Deferoxamine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000279	0.00125	CcSEcCtD
Deferoxamine—Hallucination—Prednisone—systemic scleroderma	0.000277	0.00125	CcSEcCtD
Deferoxamine—Pruritus—Leflunomide—systemic scleroderma	0.000274	0.00123	CcSEcCtD
Deferoxamine—Connective tissue disorder—Prednisone—systemic scleroderma	0.000274	0.00123	CcSEcCtD
Deferoxamine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000273	0.00123	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000272	0.00123	CcSEcCtD
Deferoxamine—Dysuria—Methotrexate—systemic scleroderma	0.000272	0.00122	CcSEcCtD
Deferoxamine—Dizziness—Azathioprine—systemic scleroderma	0.000271	0.00122	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000266	0.0012	CcSEcCtD
Deferoxamine—Diarrhoea—Leflunomide—systemic scleroderma	0.000265	0.00119	CcSEcCtD
Deferoxamine—Urticaria—Lisinopril—systemic scleroderma	0.000265	0.00119	CcSEcCtD
Deferoxamine—Body temperature increased—Lisinopril—systemic scleroderma	0.000263	0.00119	CcSEcCtD
Deferoxamine—Abdominal pain—Lisinopril—systemic scleroderma	0.000263	0.00119	CcSEcCtD
Deferoxamine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000262	0.00118	CcSEcCtD
Deferoxamine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000262	0.00118	CcSEcCtD
Deferoxamine—Vomiting—Azathioprine—systemic scleroderma	0.000261	0.00117	CcSEcCtD
Deferoxamine—Eye disorder—Prednisone—systemic scleroderma	0.00026	0.00117	CcSEcCtD
Deferoxamine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00026	0.00117	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—systemic scleroderma	0.000259	0.00117	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—systemic scleroderma	0.000259	0.00117	CcSEcCtD
Deferoxamine—Headache—Azathioprine—systemic scleroderma	0.000257	0.00116	CcSEcCtD
Deferoxamine—Dizziness—Leflunomide—systemic scleroderma	0.000256	0.00115	CcSEcCtD
Deferoxamine—Renal failure—Methotrexate—systemic scleroderma	0.000255	0.00115	CcSEcCtD
Deferoxamine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000253	0.00114	CcSEcCtD
Deferoxamine—Angiopathy—Prednisone—systemic scleroderma	0.000253	0.00114	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000252	0.00113	CcSEcCtD
Deferoxamine—Immune system disorder—Prednisone—systemic scleroderma	0.000251	0.00113	CcSEcCtD
Deferoxamine—Pain—Mycophenolate mofetil—systemic scleroderma	0.00025	0.00112	CcSEcCtD
Deferoxamine—Arrhythmia—Prednisone—systemic scleroderma	0.000249	0.00112	CcSEcCtD
Deferoxamine—Vomiting—Leflunomide—systemic scleroderma	0.000246	0.00111	CcSEcCtD
Deferoxamine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000245	0.0011	CcSEcCtD
Deferoxamine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000245	0.0011	CcSEcCtD
Deferoxamine—Nausea—Azathioprine—systemic scleroderma	0.000244	0.0011	CcSEcCtD
Deferoxamine—Headache—Leflunomide—systemic scleroderma	0.000243	0.00109	CcSEcCtD
Deferoxamine—Erythema—Prednisone—systemic scleroderma	0.000242	0.00109	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000239	0.00107	CcSEcCtD
Deferoxamine—Pruritus—Lisinopril—systemic scleroderma	0.000236	0.00106	CcSEcCtD
Deferoxamine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000235	0.00106	CcSEcCtD
Deferoxamine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000232	0.00104	CcSEcCtD
Deferoxamine—Headache—Mycophenolic acid—systemic scleroderma	0.000232	0.00104	CcSEcCtD
Deferoxamine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000231	0.00104	CcSEcCtD
Deferoxamine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000231	0.00104	CcSEcCtD
Deferoxamine—Nausea—Leflunomide—systemic scleroderma	0.00023	0.00104	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00023	0.00103	CcSEcCtD
Deferoxamine—Vision blurred—Prednisone—systemic scleroderma	0.000228	0.00103	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—systemic scleroderma	0.000228	0.00103	CcSEcCtD
Deferoxamine—Diarrhoea—Lisinopril—systemic scleroderma	0.000228	0.00103	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—systemic scleroderma	0.000224	0.00101	CcSEcCtD
Deferoxamine—Angioedema—Prednisone—systemic scleroderma	0.000221	0.000997	CcSEcCtD
Deferoxamine—Dizziness—Lisinopril—systemic scleroderma	0.00022	0.000991	CcSEcCtD
Deferoxamine—Nausea—Mycophenolic acid—systemic scleroderma	0.00022	0.000989	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—systemic scleroderma	0.000217	0.000979	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—systemic scleroderma	0.000217	0.000976	CcSEcCtD
Deferoxamine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000215	0.000968	CcSEcCtD
Deferoxamine—Vomiting—Lisinopril—systemic scleroderma	0.000212	0.000953	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—systemic scleroderma	0.000211	0.00095	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—systemic scleroderma	0.00021	0.000946	CcSEcCtD
Deferoxamine—Convulsion—Prednisone—systemic scleroderma	0.00021	0.000945	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00021	0.000944	CcSEcCtD
Deferoxamine—Headache—Lisinopril—systemic scleroderma	0.000209	0.000939	CcSEcCtD
Deferoxamine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000206	0.000929	CcSEcCtD
Deferoxamine—Myalgia—Prednisone—systemic scleroderma	0.000206	0.000929	CcSEcCtD
Deferoxamine—Arthralgia—Prednisone—systemic scleroderma	0.000206	0.000929	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000205	0.000922	CcSEcCtD
Deferoxamine—Erythema—Methotrexate—systemic scleroderma	0.000203	0.000912	CcSEcCtD
Deferoxamine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000899	CcSEcCtD
Deferoxamine—Nausea—Lisinopril—systemic scleroderma	0.000198	0.00089	CcSEcCtD
Deferoxamine—Oedema—Prednisone—systemic scleroderma	0.000198	0.00089	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000198	0.00089	CcSEcCtD
Deferoxamine—Infection—Prednisone—systemic scleroderma	0.000197	0.000884	CcSEcCtD
Deferoxamine—Shock—Prednisone—systemic scleroderma	0.000195	0.000876	CcSEcCtD
Deferoxamine—Nervous system disorder—Prednisone—systemic scleroderma	0.000194	0.000873	CcSEcCtD
Deferoxamine—Tachycardia—Prednisone—systemic scleroderma	0.000193	0.000869	CcSEcCtD
Deferoxamine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000193	0.000869	CcSEcCtD
Deferoxamine—Skin disorder—Prednisone—systemic scleroderma	0.000192	0.000865	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—systemic scleroderma	0.000191	0.000859	CcSEcCtD
Deferoxamine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000835	CcSEcCtD
Deferoxamine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000823	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—systemic scleroderma	0.000181	0.000816	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.00018	0.000811	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisone—systemic scleroderma	0.000178	0.000799	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—systemic scleroderma	0.000176	0.00079	CcSEcCtD
Deferoxamine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000173	0.00078	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—systemic scleroderma	0.000172	0.000776	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—systemic scleroderma	0.000172	0.000776	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000171	0.000771	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000165	0.000744	CcSEcCtD
Deferoxamine—Infection—Methotrexate—systemic scleroderma	0.000164	0.000739	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000162	0.00073	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000162	0.000728	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000162	0.000728	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—systemic scleroderma	0.000161	0.000723	CcSEcCtD
Deferoxamine—Urticaria—Prednisone—systemic scleroderma	0.000157	0.000707	CcSEcCtD
Deferoxamine—Abdominal pain—Prednisone—systemic scleroderma	0.000156	0.000704	CcSEcCtD
Deferoxamine—Body temperature increased—Prednisone—systemic scleroderma	0.000156	0.000704	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—systemic scleroderma	0.000154	0.000695	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000151	0.000678	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—systemic scleroderma	0.000148	0.000668	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—systemic scleroderma	0.000147	0.000663	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisone—systemic scleroderma	0.000146	0.000656	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000143	0.000642	CcSEcCtD
Deferoxamine—Pain—Methotrexate—systemic scleroderma	0.000141	0.000636	CcSEcCtD
Deferoxamine—Pruritus—Prednisone—systemic scleroderma	0.00014	0.00063	CcSEcCtD
Deferoxamine—Diarrhoea—Prednisone—systemic scleroderma	0.000135	0.000609	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000135	0.000608	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—systemic scleroderma	0.000131	0.000591	CcSEcCtD
Deferoxamine—Dizziness—Prednisone—systemic scleroderma	0.000131	0.000589	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—systemic scleroderma	0.000131	0.000588	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—systemic scleroderma	0.000131	0.000588	CcSEcCtD
Deferoxamine—Vomiting—Prednisone—systemic scleroderma	0.000126	0.000566	CcSEcCtD
Deferoxamine—Headache—Prednisone—systemic scleroderma	0.000124	0.000558	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000122	0.000548	CcSEcCtD
Deferoxamine—Nausea—Prednisone—systemic scleroderma	0.000118	0.000529	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—systemic scleroderma	0.000117	0.000526	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—systemic scleroderma	0.000113	0.000509	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—systemic scleroderma	0.000109	0.000492	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—systemic scleroderma	0.000105	0.000473	CcSEcCtD
Deferoxamine—Headache—Methotrexate—systemic scleroderma	0.000104	0.000466	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—systemic scleroderma	9.82e-05	0.000442	CcSEcCtD
